190 related articles for article (PubMed ID: 14624139)
1. Pharmacologic prevention of both restenosis and atherosclerosis progression: AGI-1067, probucol, statins, folic acid and other therapies.
Tardif JC; Grégoire J; Lavoie MA; L'Allier PL
Curr Opin Lipidol; 2003 Dec; 14(6):615-20. PubMed ID: 14624139
[TBL] [Abstract][Full Text] [Related]
2. Vascular protectants for the treatment of atherosclerosis.
Tardif JC; Grégoire J; Lavoie MA; L'Allier PL
Expert Rev Cardiovasc Ther; 2003 Sep; 1(3):385-92. PubMed ID: 15030266
[TBL] [Abstract][Full Text] [Related]
3. Clinical results with AGI-1067: a novel antioxidant vascular protectant.
Tardif JC
Am J Cardiol; 2003 Feb; 91(3A):41A-49A. PubMed ID: 12645643
[TBL] [Abstract][Full Text] [Related]
4. Prevention of restenosis with antioxidants: mechanisms and implications.
Tardif JC; Grégoire J; L'Allier PL
Am J Cardiovasc Drugs; 2002; 2(5):323-34. PubMed ID: 14727962
[TBL] [Abstract][Full Text] [Related]
5. Antioxidants and atherosclerosis: emerging drug therapies.
Tardif JC
Curr Atheroscler Rep; 2005 Feb; 7(1):71-7. PubMed ID: 15683606
[TBL] [Abstract][Full Text] [Related]
6. Antioxidants: the good, the bad and the ugly.
Tardif JC
Can J Cardiol; 2006 Feb; 22 Suppl B(Suppl B):61B-65B. PubMed ID: 16498514
[TBL] [Abstract][Full Text] [Related]
7. AGI-1067: a novel vascular protectant for prevention of restenosis.
Franks AM; Gardner SF
Ann Pharmacother; 2006 Jan; 40(1):66-73. PubMed ID: 16303986
[TBL] [Abstract][Full Text] [Related]
8. Experimental and clinical studies show that the probucol derivative AGI-1067 prevents vascular growth.
Doggrell SA
Expert Opin Investig Drugs; 2003 Nov; 12(11):1855-9. PubMed ID: 14585060
[TBL] [Abstract][Full Text] [Related]
9. Effects of AGI-1067 and probucol after percutaneous coronary interventions.
Tardif JC; Grégoire J; Schwartz L; Title L; Laramée L; Reeves F; Lespérance J; Bourassa MG; L'Allier PL; Glass M; Lambert J; Guertin MC;
Circulation; 2003 Feb; 107(4):552-8. PubMed ID: 12566365
[TBL] [Abstract][Full Text] [Related]
10. AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Serebruany VL; Malinin A; Eisert C; Ong S
Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):635-41. PubMed ID: 17605642
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic approaches to restenosis prevention.
Douglas JS
Am J Cardiol; 2007 Sep; 100(5A):10K-6K. PubMed ID: 17719348
[TBL] [Abstract][Full Text] [Related]
12. AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent.
Sundell CL; Somers PK; Meng CQ; Hoong LK; Suen KL; Hill RR; Landers LK; Chapman A; Butteiger D; Jones M; Edwards D; Daugherty A; Wasserman MA; Alexander RW; Medford RM; Saxena U
J Pharmacol Exp Ther; 2003 Jun; 305(3):1116-23. PubMed ID: 12626663
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: a novel antioxidant and anti-inflammatory agent.
Kunsch C; Luchoomun J; Grey JY; Olliff LK; Saint LB; Arrendale RF; Wasserman MA; Saxena U; Medford RM
J Pharmacol Exp Ther; 2004 Mar; 308(3):820-9. PubMed ID: 14617690
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological inhibition of coronary restenosis: systemic and local approaches.
Guerra E; Byrne RA; Kastrati A
Expert Opin Pharmacother; 2014 Oct; 15(15):2155-71. PubMed ID: 25145263
[TBL] [Abstract][Full Text] [Related]
15. Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial.
Tardif JC; Grégoire J; L'Allier PL; Ibrahim R; Anderson TJ; Reeves F; Title LM; Schampaert E; LeMay M; Lespérance J; Scott R; Guertin MC; Brennan ML; Hazen SL; Bertrand OF;
Atherosclerosis; 2008 Mar; 197(1):480-6. PubMed ID: 17214993
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial.
Yokoi H; Daida H; Kuwabara Y; Nishikawa H; Takatsu F; Tomihara H; Nakata Y; Kutsumi Y; Ohshima S; Nishiyama S; Seki A; Kato K; Nishimura S; Kanoh T; Yamaguchi H
J Am Coll Cardiol; 1997 Oct; 30(4):855-62. PubMed ID: 9316509
[TBL] [Abstract][Full Text] [Related]
17. Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease.
Wasserman MA; Sundell CL; Kunsch C; Edwards D; Meng CQ; Medford RM
Am J Cardiol; 2003 Feb; 91(3A):34A-40A. PubMed ID: 12645642
[TBL] [Abstract][Full Text] [Related]
18. Low daily dose of antioxidant probucol decreases incidence and severity of restenosis after transluminal coronary balloon angioplasty.
Kaminnyi AI; Lankin VZ; Samko AN; Sozykin AL; Provatorov SI; Konovalova GG; Perepelitsa EI; Tikhaze AK; Polevaya TY; Kukharchuk VV; Belenkov YN
Bull Exp Biol Med; 2005 Feb; 139(2):183-5. PubMed ID: 16027801
[TBL] [Abstract][Full Text] [Related]
19. Prevention of restenosis after angioplasty in small coronary arteries with probucol.
Rodés J; Côté G; Lespérance J; Bourassa MG; Doucet S; Bilodeau L; Bertrand OF; Harel F; Gallo R; Tardif JC
Circulation; 1998 Feb; 97(5):429-36. PubMed ID: 9490236
[TBL] [Abstract][Full Text] [Related]
20. Anti-atherosclerotic and anti-diabetic properties of probucol and related compounds.
Tanous D; Hime N; Stocker R
Redox Rep; 2008; 13(2):48-59. PubMed ID: 18339247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
